Jun Li1, David A Siegel2, Jessica B King3. 1. Epidemiology and Applied Research Branch, Division of Cancer and Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA. Electronic address: ffa2@cdc.gov. 2. Epidemiology and Applied Research Branch, Division of Cancer and Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA; Epidemic Intelligence Service, CDC, Atlanta, GA. 3. Cancer Surveillance Branch, Division of Cancer and Prevention, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, GA.
Abstract
PURPOSE: Current literature shows different findings on the contemporary trends of distant-stage prostate cancer incidence, in part, due to low study population coverage and wide age groupings. This study aimed to examine the stage-specific incidence rates and trends of prostate cancer by age (5-year grouping), race, and ethnicity using nationwide cancer registry data. METHODS: Data on prostate cancer cases came from the 2004-2014 United States Cancer Statistics data set. We calculated stage-specific incidence and 95% confidence intervals by age (5-year age grouping), race, and ethnicity. To measure the changes in rates over time, we calculated annual percentage change (APC). RESULTS: We identified 2,137,054 incident prostate cancers diagnosed during 2004-2014, with an age-adjusted incidence rate of 453.8 per 100,000. Distant-stage prostate cancer incidence significantly decreased during 2004-2010 (APC = -1.2) and increased during 2010-2014 (APC = 3.3). Significant increases in distant prostate cancer incidence also occurred in men aged older than or equal to 50 years except men aged 65-74 and older than or equal to 85 years, in men with white race (APC = 3.9), and non-Hispanic ethnicity (APC = 3.5). CONCLUSIONS: Using data representing over 99% of U.S. population, we found that incidence rates of distant-stage prostate cancer significantly increased during 2010-2014 among men in certain ages, in white, and with non-Hispanic ethnicity. Published by Elsevier Inc.
PURPOSE: Current literature shows different findings on the contemporary trends of distant-stage prostate cancer incidence, in part, due to low study population coverage and wide age groupings. This study aimed to examine the stage-specific incidence rates and trends of prostate cancer by age (5-year grouping), race, and ethnicity using nationwide cancer registry data. METHODS: Data on prostate cancer cases came from the 2004-2014 United States Cancer Statistics data set. We calculated stage-specific incidence and 95% confidence intervals by age (5-year age grouping), race, and ethnicity. To measure the changes in rates over time, we calculated annual percentage change (APC). RESULTS: We identified 2,137,054 incident prostate cancers diagnosed during 2004-2014, with an age-adjusted incidence rate of 453.8 per 100,000. Distant-stage prostate cancer incidence significantly decreased during 2004-2010 (APC = -1.2) and increased during 2010-2014 (APC = 3.3). Significant increases in distant prostate cancer incidence also occurred in men aged older than or equal to 50 years except men aged 65-74 and older than or equal to 85 years, in men with white race (APC = 3.9), and non-Hispanic ethnicity (APC = 3.5). CONCLUSIONS: Using data representing over 99% of U.S. population, we found that incidence rates of distant-stage prostate cancer significantly increased during 2010-2014 among men in certain ages, in white, and with non-Hispanic ethnicity. Published by Elsevier Inc.
Entities:
Keywords:
Cancer incidence; Cancer stage; Prostate cancer
Authors: H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman Journal: J Urol Date: 2013-05-06 Impact factor: 7.450
Authors: Jim C Hu; Paul Nguyen; Jialin Mao; Joshua Halpern; Jonathan Shoag; Jason D Wright; Art Sedrakyan Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777
Authors: Richard M Hoffman; Angela L W Meisner; Wadih Arap; Marc Barry; Satyan K Shah; Steven B Zeliadt; Charles L Wiggins Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-08 Impact factor: 4.254
Authors: Florian Rosar; Sebastian Dewes; Martin Ries; Andrea Schaefer; Fadi Khreish; Stephan Maus; Hendrik Bohnenberger; Johannes Linxweiler; Mark Bartholomä; Carsten Ohlmann; Samer Ezziddin Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-03 Impact factor: 9.236
Authors: Minh-Phuong Huynh-Le; Tor Åge Myklebust; Christine H Feng; Roshan Karunamuni; Tom Børge Johannesen; Anders M Dale; Ole A Andreassen; Tyler M Seibert Journal: Cancer Date: 2020-01-03 Impact factor: 6.860
Authors: S Jane Henley; Elizabeth M Ward; Susan Scott; Jiemin Ma; Robert N Anderson; Albert U Firth; Cheryll C Thomas; Farhad Islami; Hannah K Weir; Denise Riedel Lewis; Recinda L Sherman; Manxia Wu; Vicki B Benard; Lisa C Richardson; Ahmedin Jemal; Kathleen Cronin; Betsy A Kohler Journal: Cancer Date: 2020-03-12 Impact factor: 6.921
Authors: Susan Feyerabend; Fred Saad; Nolen Joy Perualila; Suzy Van Sanden; Joris Diels; Tetsuro Ito; Peter De Porre; Karim Fizazi Journal: Target Oncol Date: 2019-12 Impact factor: 4.493
Authors: Jeff M Slezak; Stephen K Van Den Eeden; Kimberly L Cannavale; Gary W Chien; Steven J Jacobsen; Chun R Chao Journal: Cancer Med Date: 2020-09-23 Impact factor: 4.452